iSpecimen Closes $4.5M AI Asset Purchase; Foldlab Takes 53.6% Stake

What happened

iSpecimen Inc. (Nasdaq: ISPC), a Woburn, Massachusetts-based provider of human biospecimens for medical research, said in a Form 8-K filed Nov. 5 that it closed its acquisition of a set of artificial intelligence assets from Foldlab AI Ltd., a British Columbia company, on Nov. 2.

The assets include AI software, models, source code, data rights and intellectual property, among them products described in the filing as the Disease-Associated Protein Discovery AI Agent and the Disease Trend Prediction and Monitoring AI Model.

The total purchase price was $4.5 million. iSpecimen paid $750,000 in cash at closing from existing cash, agreed to two milestone payments of $625,000 each (up to $1.25 million) payable only if each AI product is delivered, tested and accepted under criteria in the agreement, and issued 2,907,977 shares of common stock worth $2.5 million.

The share count was set by dividing $2.5 million by $0.8597, the volume-weighted average price of iSpecimen stock over the ten trading days from Oct. 19 to Oct. 30, 2026. iSpecimen closed at $0.808 on the event date, down 4.15% from $0.843 the prior session, according to the price data.

Because 2,518,590 shares were outstanding as of the Aug. 12 record date, the new shares give Foldlab approximately 53.6% of the company, a change in control under Item 5.01. Zhengkang (Jacob) Shao is Foldlab's sole director and sole shareholder and may be deemed to beneficially own the shares. The filing says no funds were used by Foldlab or Shao to acquire them. No change was made to iSpecimen's board or executive officers.

The restrictions on Foldlab's shares

An amendment to the September 4 asset purchase agreement, signed Nov. 2, changed how the shares are held. Because no third-party escrow agent was engaged, the shares were not placed in escrow; they were issued in restricted book-entry form in Foldlab's name at iSpecimen's transfer agent, Broadridge, with restrictive legends and a stop-transfer instruction.

A five-year lock-up with no leak-out applies: Foldlab and any transferee may not sell, transfer, pledge, hedge, short, lend or otherwise dispose of the shares or any related economic interest during that period. The restrictions are enforced through the legends, the stop-transfer instruction and a separate voting rights agreement.

iSpecimen may set off amounts Foldlab owes it under the agreement and can keep the transfer restriction in place on any shares tied to a claim asserted before the fifth anniversary until that claim is resolved.

Under the voting rights agreement, Foldlab gave iSpecimen an irrevocable proxy to vote the shares on matters involving issuance, listing, transfer restrictions, recapitalization, change of control or implementation of the transaction, and may not vote in ways that would reasonably be expected to impair the company, the acquired assets, the transaction, its Nasdaq listing or securities-law compliance. Foldlab otherwise keeps voting rights, including in director elections.

What this means

A Form 8-K is the report a US public company must file with the SEC within four business days of certain major events. The numbered items in the filing say which triggers applied here: 1.01 for entering a material agreement, 2.01 for completing an acquisition, 3.02 for an unregistered sale of equity, 5.01 for a change in control and 7.01 for the press release furnished under Regulation FD, which requires companies to disclose material information to all investors at once rather than selectively.

Item 3.02 exists because iSpecimen sold the shares without registering them under the Securities Act. The filing cites Regulation S, which covers offers and sales made outside the United States to non-US persons — the basis being that Foldlab is not a US person and the issuance was an offshore transaction — and, alternatively, Section 4(a)(2), the private-placement exemption. The shares are restricted securities and iSpecimen has no obligation to register their resale.

The price mechanism matters for readers watching dilution. Rather than a fixed number of shares, the deal fixed a dollar amount, $2.5 million, and converted it at the stock's ten-day volume-weighted average price. A volume-weighted average weights each day's price by how much stock traded that day, which smooths out single-day swings. If the stock had been higher over that window, Foldlab would have received fewer shares.

It is notable that stock with a five-year lock-up and no leak-out still counts toward the 53.6% control figure: control is measured by voting and ownership, not by whether the holder can sell. The irrevocable proxy narrows what Foldlab can do with that voting power on a defined list of corporate actions, while leaving it the right to vote in director elections.

The filing does not say why iSpecimen bought the AI assets or how it expects to use them, beyond listing the products acquired. The milestone structure means $1.25 million of the stated $4.5 million price is contingent: no milestone payment is earned for partial performance, incomplete delivery, a failed test or an unresolved material defect. The filing also states that no financial statements or pro forma figures were required because the acquired assets do not constitute a business under SEC accounting rules.